Article
T cell vaccination benefits relapsing progressive multiple sclerosis patients: a randomized, double-blind clinical trial.
PloS one - 1 Jan 2012
Karussis Dimitrios, Shor Hagai, Yachnin Julia, Lanxner Naama, Amiel Merav, Baruch Keren, Keren-Zur Yael, Haviv Ofra, Filippi Massimo, Petrou Panayiota, Hajag Shalom, Vourka-Karussis Urania, Vaknin-Dembinsky Adi, Khoury Salim, Abramsky Oded, Atlan Henri, Cohen Irun R, Abulafia-Lapid Rivka
Abstract excerpt
BACKGROUND: T-cell vaccination (TCV) for multiple sclerosis (MS) refers to treatment with autologous anti-myelin T-cells, attenuated by irradiation. Previously published clinical trials have been all open-labeled. AIM: To evaluate the safety and efficacy of TCV in progressive MS, in a double-blind, controlled clinical trial. METHODOLOGY: Twenty-six patients with relapsing-progressive MS were enrolled in the study...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.